文献速递血脂与心血管预防

纯合子家族性高胆固醇血症生存取决于治疗中血清胆固醇水平

Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol.
PubMed 文献 · Eur Heart J · 2018-01-01

该回顾性研究纳入1990至2014年南非和英国133例既往未用他汀的纯合子家族性高胆固醇血症患者,按治疗中血清胆固醇水平四分位分组,随访25年。结果显示治疗中胆固醇>15.1 mmol/L者全因死亡风险显著高于<8.1 mmol/L者(HR 11.5),8.1-15.1 mmol/L者HR 3.6,心血管死亡和MACE also差异显著。

要点

  • 治疗中血清胆固醇>15.1 mmol/L者全因死亡风险是<8.1 mmol/L者的11.5倍。
  • 治疗中胆固醇8.1-15.1 mmol/L者全因死亡风险仍为<8.1 mmol/L者的3.6倍。
  • 综合降脂措施(他汀、依折麦布、脂蛋白血浆置换、evolocumab)降低胆固醇程度决定生存。

核心结论

  • 综合降脂治疗达到的血清胆固醇降低程度是纯合子家族性高胆固醇血症患者生存的主要决定因素。

研究设计与样本

  • 回顾性调查1990至2014年南非和英国133例既往未用他汀的纯合子家族性高胆固醇血症患者,按治疗中血清胆固醇水平四分位分组,随访25年,采用Cox和竞争风险回归分析。

主要发现

  • 治疗中血清胆固醇>15.1 mmol/L者(第四四分位)全因死亡风险比为11.5,对比第一四分位(<8.1 mmol/L)。
  • 治疗中血清胆固醇8.1-15.1 mmol/L者(第二和第三四分位合并)全因死亡风险比为3.6,对比第一四分位。
  • 上述差异具有统计学显著性(P < 0.001),校正混杂因素后仍显著(P = 0.04)。
  • 心血管死亡和主要不良心血管事件(MACE)在各四分位间 also 存在显著差异。

临床怎么用

  • 对纯合子家族性高胆固醇血症患者,应积极联合他汀、依折麦布、脂蛋白血浆置换和evolocumab等降脂措施,将治疗中血清胆固醇降至尽可能低的水平以改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Homozygous familial hypercholesterolaemia (FH) is a rare inherited disorder characterized by extreme hypercholesterolaemia from birth, accelerated atherosclerosis, and premature death. Many forms of lipid-lowering therapies have been used in the past, but definitive evidence of benefit has been lacking. We therefore undertook a retrospective survey of lipid levels and clinical outcomes of FH homozygotes treated with a combination of lipid-lowering measures between 1990 and 2014 in South Africa and the UK. METHODS AND RESULTS: We divided 133 previously statin-naive homozygotes into quartiles according to their on-treatment levels of serum cholesterol and compared the occurrence of any death, cardiovascular death, and major adverse cardiovascular events (MACE) between the quartiles during 25 years of follow-up, using Cox and competing risks regression analysis. Patients in Quartile 4, with an on-treatment serum cholesterol >15.1 mmol/L, had a hazard ratio of 11.5 for any death compared with those in Quartile 1, with an on-treatment cholesterol of < 8.1 mmol/L. Those in Quartiles 2 and 3 combined, with on-treatment cholesterol of 8.1-15.1 mmol/L had a hazard ratio of 3.6 compared with Quartile 1. These differences were statistically significant (P < 0.001) and remained so after adjustments for confounding factors (P = 0.04). Significant differences between quartiles were also evident for cardiovascular deaths and MACE. CONCLUSION: These findings provide unequivocal evidence that the extent of reduction of serum cholesterol achieved by a combination of therapeutic measures, including statins, ezetimibe, lipoprotein apheresis, and evolocumab, is a major determinant of survival in homozygous FH.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Thompson GR, Blom DJ, Marais AD, et al. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J. 2018. PMID: 29106543. doi:10.1093/eurheartj/ehx317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。